Pulse Journal Club Active Debates Trending Explore Researchers

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Acceleration of new medicines–CMC lessons learned from emergency use authorizations | Synapse

March 4, 2024Open Access

Acceleration of new medicines–CMC lessons learned from emergency use authorizations

Key Points

Key points are not available for this paper at this time.

Abstract

Abstract The American Association of Pharmaceutical Scientists (AAPS) Chemistry, Manufacturing, and Control (CMC) Community hosted a virtual panel discussion on July 15, 2022, to provide a forum to discuss industry and regulator CMC challenges associated with emergency use authorizations.

Read Full Paperexternally

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Bernstein et al. (Mon,) studied this question.

synapsesocial.com/papers/68e75ca2b6db6435876d3bc9 https://doi.org/https://doi.org/10.1186/s41120-023-00089-2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Global health authorities review and approval trends for CMC post approval changes 2018-20242026
2CMC obstacles in cell and gene therapy: four solutions to solve six challenges2021
3Exploration & Outcomes of Emergency Use Authorization during theCOVID-19 Pandemic in the United States2024
4Learning from the EMA experience: common CMC deficiencies in marketing authorisation applications over the past decade2025
5Balancing ethical norms and duties for the introduction of new medicines through conditional marketing authorization: a research agenda2024 · 5 citations